Article citationsMore>>

Martinez de Dueñas, E., Ochoa Aranda, E., Blancas Lopez-Barajas, I., Ferrer Magda-lena, T., Bandrés Moya, F., Chicharro García, L.M., et al. (2014) Adjusting the Dose of Tamoxifen in Patients with Early Breast Cancer and CYP2D6 Poor Metabolizer Phenotype. The Breast, 23, 400-406.
https://doi.org/10.1016/j.breast.2014.02.008

has been cited by the following article:

• TITLE: Advances in Cytochrome P450 in Tumor Therapy

  AUTHORS: Junhua Ming, Qing Zhang

  KEYWORDS: Cytochrome P450, Mechanism, Targeted Drugs, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.8, August 12, 2025

  ABSTRACT: Cytochrome P450 (CYP450) is a family of heme proteins capable of self-oxidation and is a type of monooxygenase. It was first discovered in the microsomes of liver cells and is distributed throughout various tissues and organs in the body, primarily localized on the inner membranes of the endoplasmic reticulum and mitochondria. CYP450 is involved in the metabolism of various endogenous and exogenous carcinogens and plays a significant role in the metabolism of numerous anticancer drugs and the development of tumors such as lung cancer, thyroid cancer, colorectal cancer, and breast cancer. Therefore, the development of CYP450-related anticancer targeted drugs and their expression in tumors have become a hot topic. This review aims to focus on the progress and clinical translation challenges of CYP450 in tumors.